NASDAQ · MBOT

Microbot Medical, Inc.

$1.66 -$0.05 (-2.92%) 1D Market open

Key Metrics

$114.85M
Market cap
P/E · TTM
$105.00K
Revenue · TTM
−$14.21M
Net income
EPS · TTM $-0.46
Dividend yield
Free cash flow −$15.38M
Beta · 1Y 1.86
EBITDA · TTM −$16.00M
Gross margin 1.9%

The Story So Far

LAST 6 MONTHS PRIMARY SOURCES ONLY
  • Jul 21
    A material event was filed (Form 8-K).

    8-K - Microbot Medical Inc. (0000883975) (Filer)

    RECEIPT: SEC FORM 8-K, TIMESTAMPED
  • Jul 16
    Money rotated out of high-beta cohorts market-wide.

    High-beta names lagged the blue-chips by 20.3 points over ten sessions around this date. Stocks in that cohort weren't falling alone — they fell together.

    RECEIPT: ROTATION GAUGE, LIVE
  • May 22
    From its Mar 11 high, the share price fell 40%.

    Peak close $2.85 on Mar 11; trough close $1.71 on May 22. The drawdown is the fact — the chapters around it are the context.

    RECEIPT: PRICE SERIES, PEAK-TO-TROUGH -40%
  • May 14
    The stock moved -14.7% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, May 14
  • Feb 24
    The stock moved +23.9% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Feb 24

The story updates itself as events post · The wolf reports; you decide

Snapshot

Market cap$114.85M
Enterprise value
Shares outstanding67.2M
52-wk range$1.60 – $4.67
Avg volume · 20D1.2M
Net cash
Book value / share$2.38
IndustrySurgical & Medical Instruments & Apparatus
ExchangeNASDAQ
About Microbot Medical, Inc.
IPO dateMar 25, 1992
Employees22

Microbot Medical Inc is a medical device company specializing in the research, design, and development of next-generation robotic endoluminal surgery devices targeting the minimally invasive surgery space.

Wolf Grade COMING SOON

The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.

Valuation

P/E
P/S1,093.83
P/FCF
EV/EBITDA
EV/Sales
Graham №

Profitability

Gross 1.9%
Operating -15,278.1%
Net -13,535.2%
FCF -14,647.6%
ROE / ROIC -36.6% · —

Financial Health

Current ratio22.59
Quick ratio21.93
Debt / equity
Debt / EBITDA
Net cash
Working capital$73.14M

Cash Flow · TTM

Operating CF −$15.23M
Capex −$155.00K
Free cash flow −$15.38M
Buybacks
Dividends paid
Shareholder yield

Piotroski F-Score

3 / 9
Weak fundamentals · 3 of 9 signals passing

Altman Z-Score

15.9
Safe zone (> 2.99) · bankruptcy risk negligible

Graham Number vs Price

Requires positive earnings and book value
Fundamentals through 2026-03-31 · computed by TickerWolf from SEC filings